{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:53:08Z","timestamp":1762005188195,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 1023"],"award-info":[{"award-number":["EXC 1023"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00611","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:58:57Z","timestamp":1588913937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report"],"prefix":"10.3389","volume":"10","author":[{"given":"Anne","family":"Fr\u00f6hlich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Niebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Egger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido M.","family":"Kukuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieta","family":"Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Sirokay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Landsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000472579","article-title":"Primary malignant melanoma of the female urethral meatus","volume":"12","author":"Robutti","year":"1986","journal-title":"Eur Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1470-2045(08)70254-7","article-title":"Management of primary melanoma of the female urogenital tract","volume":"9","author":"Piura","year":"2008","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1111\/1346-8138.14763","article-title":"Response to imatinib in vaginal melanoma with KIT p.Val559Gly mutation previously treated with nivolumab, pembrolizumab and ipilimumab","volume":"46","author":"Komatsu-Fujii","year":"2019","journal-title":"J Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Investig J Tech Methods Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102617","DOI":"10.18632\/oncotarget.18309","article-title":"Review: oncolytic virotherapy, updates and future directions","volume":"8","author":"Fountzilas","year":"2017","journal-title":"Oncotarget."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/01.ju.0000104671.20863.47","article-title":"Outcome of surgical treatment for primary malignant melanoma of the female urethra","volume":"171","author":"DiMarco","year":"2004","journal-title":"J Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer."},{"key":"B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/IGC.0000000000000198","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas","volume":"24","author":"Leitao","year":"2014","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gore.2016.04.001","article-title":"Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract","volume":"16","author":"Schiavone","year":"2016","journal-title":"Gynecol Oncol Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.it.2018.01.007","article-title":"Immunology of the uterine and vaginal mucosae","volume":"39","author":"Zhou","year":"2018","journal-title":"Trends Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.4049\/jimmunol.165.9.5077","article-title":"Vaginal mucosa serves as an inductive site for tolerance","volume":"165","author":"Black","year":"2000","journal-title":"J Immunol Baltim Md."},{"key":"B18","doi-asserted-by":"crossref","unstructured":"NiederkornJY\n          22707951Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?2012","DOI":"10.3389\/fimmu.2012.00148"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1038\/ncomms7100","article-title":"Vaginal type-II mucosa is an inductive site for primary CD8+ T-cell mucosal immunity","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","article-title":"Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions","volume":"23","author":"Nishino","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jdcr.2017.02.003","article-title":"Talimogene laherparepvec for regionally advanced merkel cell carcinoma: a report of 2 cases","volume":"3","author":"Blackmon","year":"2017","journal-title":"JAAD Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-018-0337-7","article-title":"Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series","volume":"6","author":"Sun","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2014.03.031","article-title":"Update on primary mucosal melanoma","volume":"71","author":"Tacastacas","year":"2014","journal-title":"J Am Acad Dermatol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:59:01Z","timestamp":1588913941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":27,"alternative-id":["10.3389\/fonc.2020.00611"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00611","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"article-number":"611"}}